Purple Biotech Management

Management criteria checks 3/4

Purple Biotech's CEO is Gil Efron, appointed in Jul 2022, has a tenure of 1.92 years. total yearly compensation is $1.04M, comprised of 29.6% salary and 70.4% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth €54.81K. The average tenure of the management team and the board of directors is 2.9 years and 4 years respectively.

Key information

Gil Efron

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage29.6%
CEO tenure1.9yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gil Efron's remuneration changed compared to Purple Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$308k

-US$20m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$365k

-US$22m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$357k

-US$18m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$758kUS$266k

-US$29m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$579kUS$263k

-US$5m

Compensation vs Market: Gil's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD406.04K).

Compensation vs Earnings: Gil's compensation has been consistent with company performance over the past year.


CEO

Gil Efron (58 yo)

1.9yrs

Tenure

US$1,040,342

Compensation

Mr. Gil Efron, CPA, M.A., serves as Chief Executive Officer of Purple Biotech Ltd. since July 10, 2022. He served as Chief Financial Officer at Purple Biotech Ltd.(formerly known as Kitov Pharma Ltd) sinc...


Leadership Team

NamePositionTenureCompensationOwnership
Gil Efron
Chief Executive Officer1.9yrsUS$1.04m0.39%
$ 54.6k
Michael Schickler
Head of Clinical & Regulatory Affairs4.4yrsUS$482.37kno data
Lior Fhima
Chief Financial Officer1.6yrsno datano data
Ido Morpurgo
Vice President of Operations3.8yrsno datano data

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: 1YI1's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Simcha Rock
Independent Director10.9yrsUS$358.66kno data
Eric Rowinsky
Independent Chairman of the Board4.7yrsno datano data
Ido Agmon
Independent Director8yrsno datano data
Robert Gagnon
Independent Director3.3yrsno datano data
Eyal Gottlieb
Member of Scientific Advisory Board1.2yrsno datano data
Suzana Nahum-Zilberberg
Independent Director3.1yrsno datano data
Ori Hershkovitz
Independent Director2.5yrsno datano data
Isaac Israel
Director11.7yrsUS$381.79kno data
Scott Faucett
Member of Scientific Advisory Board9.7yrsno datano data
Sean Welton
Member of Scientific Advisory Board9.7yrsno datano data
Sunil Sharma
Member of Scientific Advisory Board1.2yrsno datano data
Steven Maron
Member of Scientific Advisory Board1.2yrsno datano data

4.0yrs

Average Tenure

50yo

Average Age

Experienced Board: 1YI1's board of directors are considered experienced (4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.